Medicare Spending and Potential Savings on Brand-name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015
The Centers for Medicare and Medicaid Services (CMS) Part D program provided prescription drug coverage to 40.8 million beneficiaries in 2016. 1 Between 2012 and 2015, the program spent $397.8 billion on prescription drugs, while beneficiary out-of-pocket costs totaled $54.6 billion. 2 Over the next decade, spending is projected to increase by 77%. 3 Several large pharmacy benefit managers (PBMs) have attempted to limit prescription drug costs by using formulary drug exclusion lists, but the extent to which these apply to Medicare Part D plans is unknown. These lists identify brand-name medications that are ineligible for coverage and specify either covered brandname and/or lower-cost, generic substitutes. We estimated potential Part D program and beneficiary savings on medications excluded by PBMs for which generic substitutes are available.
Methods | Because this study used only Medicare spending data and no patient-level data, it was exempt from institutional review board review. We identified all brand-name medications from publicly available formulary exclusion lists, using CVS Caremark's from 2012 through 2015 and Express Scripts' in 2014 and 2015, along with generic medications specified as substitutes. These PBMs are the 2 larg- 4 We limited the sample to exclusion-listed drugs for which Part D program spending data were available and for which generic substitutes were available in the same formulation. We then used 2012 through 2015 Medicare Part D drug utilization and spending data to determine actual annual CMS and beneficiary out-of-pocket spending on exclusion-listed medications. 2 Projected spending if generic substitution had taken place was estimated by averaging the annual cost of generic medications specified as substitutes that year, prioritizing bioequivalent generic substitution when available, as opposed to within-class, generic therapeutic alternatives. 5 Outof-pocket spending was calculated for both low-income subsidy beneficiaries, who qualify for additional cost-sharing assistance, and non-low-income subsidy beneficiaries. Potential savings were calculated by subtracting projected spending on generic substitutes from actual spending on exclusion-listed medications. All calculations were performed using Microsoft Excel, version 15.2.8.
Results | Between 2012 and 2015, CVS Caremark and Express
Scripts listed 154 unique medications as excluded. Specific Part D spending data were unavailable for 26 and only brandname substitutes were listed for 66. Among 62 remaining unique medications (eTable in the Supplement), 19, 27, 48, and 55 were exclusion listed each year from 2012 to 2015, including 9 (19%) and 9 (16%) by both PBMs in 2014 and 2015, respectively. Bioequivalent generic substitutes were available for 19 (31%), and generic therapeutic alternatives for 43 (69%). The CMS spent $3.6 billion on these exclusion-listed medications ( Table 1) . We estimated that CMS could have saved $2.9 billion by substituting generic medications. Potential savings increased from $138.4 million in 2012 to $1.2 billion in 2015, as more drugs were exclusion listed by PBMs.
Low-income subsidy and non-low-income subsidy beneficiaries filled 1.4 million and 2.6 million prescriptions, respec- This study was limited to brand-name medications excluded by CVS Caremark and Express Scripts; formulary exclusion lists are being increasingly adopted, leading to potentially greater savings. Furthermore, we cannot account for manufacturer rebates and discounts, which are substantial for some brand-name medications. In addition, we may have overestimated CMS spending and potential savings because we assumed complete generic and therapeutic alternative substitution. Other factors, however, including patient-specific risk-benefit considerations, may influence medication choice and not all substitutions may be clinically appropriate. 
The April 20 Cannabis Celebration and Fatal Traffic Crashes in the United States
On April 20 each year, thousands of Americans celebrate the intoxicating properties of marijuana on a popular counterculture holiday known as "4/20." Legal marijuana sales surge in anticipation of the "High Holiday," and college students report increased cannabis consumption on 4/20 itself. 1, 2 In many cities, activists and enthusiasts gather at public celebrations that feature synchronized mass consumption of cannabis at 4:20 PM. 3 Driving simulation studies indicate that higher blood Δ9-tetrahydrocannabinol concentrations decrease reaction times and increase variability in speed and lane position, while some epidemiologic studies suggest that acute cannabis intoxication increases crash risk. 4 Despite this evidence, driving after cannabis consumption is surprisingly common. 5 We hypothesized that the April 20 cannabis celebration might be associated with a population-level increase in the risk of fatal traffic crash involvement.
Methods | This study used publicly available statistical data with a waiver of approval from the University of British Columbia research ethics board. We obtained fatal motor vehicle crash data from the United States National Highway Traffic Safety Administration's Fatality Analysis Reporting System (FARS). FARS includes data on all crashes involving a motor vehicle traveling on public roadways in which at least 1 participant died within 30 days of the event. The study interval began the first 
